October 29, 2021 -- InvestorsHub NewsWire -- via Prime Time Profiles -- 

By Primetime Editorial Financial

IQSTEL (OTCQX: IQST) is a diversified technology holding company that has grown from a core telecom business into a family of tech subsidiaries ranging from Fintech to EV.

The management team is steadily reorganizing the subsidiary operations to seize overlapping market opportunities where the services of one subsidiary can be sold into the existing customer base of another subsidiary, and vice versa.

Management’s cross selling efforts have resulted in impressive revenue growth with the company on pace to realize a $60 million revenue target for 2021.

Now management is working on optimizing subsidiary redundancies to achieve operational efficiencies that can improve profit margins.

Over a year ago when management launched its efforts in full force to diversify from telecom into a broader array of technologies the share price saw a meteoric climb from $0.05 to $2.00.  The PPS has since retraced and settled in the $0.50 range plus or minus $0.10.  The volatility has settled down with the 200-day moving average climbing above the 50-day moving average late this summer.

In addition to the operational growth, management has also advanced the company’s public reporting standards implementing an independent board of directors, moving from the OTC Pink reporting standard to the OTCBB and recently to the OTCQX.


Get In Now On The Nasdaq Uplisting ROI Opportunity

The reporting standards advances are part of the company’s stated objective to uplist to Nasdaq.  Given the steady progress the company has made thus far in advancing its reporting standards, it’s reasonable to presume notable progress has been made toward a Nasdaq uplisting.

Well on track to realize $60 million in annual revenue for 2021, IQST’s market cap is still only one times revenue at $60 million.

It would not be surprising to see a definitive Nasdaq uplisting announcement Q1 2022 after the company publishes its 2021 audited annual report.  Along those same lines, seeing an announcement anytime from now until the annual report indicating the company has entered into a relationship with a sponsoring investment bank for the Nasdaq uplisting, would also not be surprising.

With only less than 150 million shares outstanding, no convertible debt on the books, and $60 million in audited annual revenue anticipated to be reported for 2021, it would not be unreasonable to see IQST’s share price reach the minimum listing requirement for a Nasdaq uplist without a recapitalization.  It could be a good time to accumulate IQST now in the calm before a Nasdaq uplisitng surge.

Source - https://primetimeprofiles.com/iqstel-inc-the-calm-before-the-surge-otcqx-iqst/

Other stocks on the move include NWBO, CYDY and ILUS.

 

SOURCE: Prime Time Profiles

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.